Matinas BioPharma (MTNB) Begins ENHANCE-IT Study of MAT9001 Against Vascepa
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Matinas BioPharma (MTNB) Misses Q4 EPS by 1c
March 9, 2020 6:33 AM EDTMatinas BioPharma (NYSE: MTNB) reported Q4 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03).
2019 was a year of significant operational progress for Matinas and we are very excited to have advanced both of our clinical stage assets, MAT9001 and MAT2203, into key efficacy trials early in 2020, commented Jerome D. Jabbour, Chief Executive Officer of Matinas. ENHANCE-IT represents a significant... More
